Efficacy and Safety of ramucirumab Combined With Nab‐paclitaxel, Lobaplatin, and S‐1 in Conversion Therapy for Unresectable Advanced Gastric Cancer: Preliminary Results of Conversion Therapy Cohort of RNPLS‐01 Trial
4 affiliations
- 1Department of Digestive Surgery Xijing Hospital of Digestive Diseases Fourth Military Medical University Xi'an China
- 2Department of General Surgery Yulin Hospital Affiliated to the First Affiliated Hospital of Xi'an Jiaotong University Yulin China
- 3Department of Pharmaceutics and Pharmacy Administration School of Pharmacy Air Force Medical University Xi'an Xi'an China
- 4Xi'an Medical University Xi'an China
Abstract
This single‐center randomized controlled trial assessed the efficacy and safety of the ramucirumab plus nab‐paclitaxel, lobaplatin, and S‐1(RNPLS) regimen for conversion therapy in unresectable advanced gastric cancer. Seventy patients were equally assigned to receive either ramucirumab, nab‐paclitaxel, lobaplatin, and S‐1(RNPLS) therapy or nab‐paclitaxel, lobaplatin, and S‐1(NPLS) chemotherapy alone. Primary endpoints included pathological complete response (pCR) and secondary endpoints encompassed R0 resection rate, objective response rate (ORR), the disease control rate (DCR), progression‐free survival (PFS), overall survival (OS), duration of response (DOR), and adverse events (AE). Although the difference in pCR rate was statistically insignificant between the two groups, the RNPLS group achieved significantly higher ORR, DCR, and R0 resection rate. Moreover, the RNPLS regimen yielded prolonged PFS, longer duration of response, and promising preliminary OS. While hypertension occurred more frequently in the RNPLS group, the incidence of grade ≥3 AEs was low and comparable in both cohorts. This exploratory single‐center randomized trial showed preliminary favorable efficacy of RNPLS regimen for conversion therapy in unresectable advanced gastric cancer with manageable toxicity.
Trial Registration: ClinicalTrials.gov: NCT06169410
Related
- Reduced-dose nanoparticle albumin-bound-paclitaxel combined with ramucirumab as second-line treatment for advanced gastric cancer: a multicenter phase II study
- Comparative Evaluation of Concurrent Carboplatin-Paclitaxel Versus Cisplatin-Etoposide Chemoradiotherapy in Unresectable Non-small Cell Lung Cancer: A Prospective Randomized Study
- Efficacy and toxicities of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel as first-line chemotherapy for unresectable pancreatic cancer: a systematic review and meta-analysis
- Sacituzumab govitecan plus toripalimab compared with toripalimab plus nab-paclitaxel for first-line treatment of unresectable, locally advanced, or metastatic triple-negative breast cancer: protocol of a multicenter, open-label, randomized phase II trial
- Case Report: From unresectable to resectable: successful conversion therapy with TACE, HAIC, envafolimab, and olaparib in advanced intrahepatic cholangiocarcinoma
BibTeX
@article{wang2026efficacy,
title = {{Efficacy and Safety of ramucirumab Combined With Nab‐paclitaxel, Lobaplatin, and S‐1 in Conversion Therapy for Unresectable Advanced Gastric Cancer: Preliminary Results of Conversion Therapy Cohort of RNPLS‐01 Trial}},
author = {Juan Wang and Wei Wang and Guanghui Xu and Shushang Liu and Longxing Jiao and Shu Wang and Chaosheng Peng and Yuxuan Ma and Xin Liu and Huade Huo and Haolin Li and Xiaohua Li and Jianjun Yang},
journal = {MedComm},
year = {2026},
month = nov,
doi = {10.1002/mco2.70958},
url = {https://doi.org/10.1002/mco2.70958},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Efficacy and Safety of ramucirumab Combined With Nab‐paclitaxel, Lobaplatin, and S‐1 in Conversion Therapy for Unresectable Advanced Gastric Cancer: Preliminary Results of Conversion Therapy Cohort of RNPLS‐01 Trial
AU - Juan Wang
AU - Wei Wang
AU - Guanghui Xu
AU - Shushang Liu
AU - Longxing Jiao
AU - Shu Wang
AU - Chaosheng Peng
AU - Yuxuan Ma
AU - Xin Liu
AU - Huade Huo
AU - Haolin Li
AU - Xiaohua Li
AU - Jianjun Yang
PY - 2026
DA - 2026/11/03
JO - MedComm
DO - 10.1002/mco2.70958
UR - https://doi.org/10.1002/mco2.70958
AB - This single‐center randomized controlled trial assessed the efficacy and safety of the ramucirumab plus nab‐paclitaxel, lobaplatin, and S‐1(RNPLS) regimen for conversion therapy in unresectable advanced gastric cancer. Seventy patients were equally assigned to receive either ramucirumab, nab‐paclitaxel, lobaplatin, and S‐1(RNPLS) therapy or nab‐paclitaxel, lobaplatin, and S‐1(NPLS) chemotherapy alone. Primary endpoints included pathological complete response (pCR) and secondary endpoints encompassed R0 resection rate, objective response rate (ORR), the disease control rate (DCR), progression‐free survival (PFS), overall survival (OS), duration of response (DOR), and adverse events (AE). Although the difference in pCR rate was statistically insignificant between the two groups, the RNPLS group achieved significantly higher ORR, DCR, and R0 resection rate. Moreover, the RNPLS regimen yielded prolonged PFS, longer duration of response, and promising preliminary OS. While hypertension occurred more frequently in the RNPLS group, the incidence of grade ≥3 AEs was low and comparable in both cohorts. This exploratory single‐center randomized trial showed preliminary favorable efficacy of RNPLS regimen for conversion therapy in unresectable advanced gastric cancer with manageable toxicity. Trial Registration: ClinicalTrials.gov: NCT06169410
SN - 2688-2663
ER -